StockData
Relmada Therapeutics, Inc. logo

Relmada Therapeutics, Inc. (RLMD) stock

RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$3.01−0.60 (-16.62%)

Close on Nov 17, 2026Market cap $321.08MP/E –Yield –

Relmada Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Relmada Therapeutics's total debt was $3.19M at Sep 30, 2018. For fiscal 2018 it was $2.66M.

Annual total debt

PeriodPeriod endValueChange
FY2018Jun 30, 2018$2.66M–

Quarterly total debt

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2019CQ3 2018Sep 30, 2018$3.19M+370.3%
Q4 FY2018CQ2 2018Jun 30, 2018$2.66M–
Q3 FY2018CQ1 2018Mar 31, 2018$1.58M–
Q2 FY2018CQ4 2017Dec 31, 2017$1.28M–
Q1 FY2018CQ3 2017Sep 30, 2017$678.88K–

More Relmada Therapeutics figures

See a number that looks wrong?